Effect of Allium macrostemon on a rat model of depression studied by using plasma lipid and acylcarnitine profiles from liquid chromatography/mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 89, Issue , 2014, Pages 122-129

  Chen, Shili ^a   Wei, Cong ^b   Gao, Peng ^a   Kong, Hongwei ^a   Jia, Zhenhua ^b   Hu, Chunxiu ^a   Dai, Weidong ^a   Wu, Yiling ^b   Xu, Guowang ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b The Integration of Traditional and Western Medical Research Academy of Hebei Province   (China)

Author keywords

Acylcarnitine; Allium macrostemon; Depression; Lipidomics; Liquid chromatography mass spectrometry

Indexed keywords

ACYLCARNITINE; ALLIUM MACROSTEMON EXTRACT; ANTIDEPRESSANT AGENT; LIPID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DEPRESSION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; IMMOBILIZATION STRESS; INFLAMMATION; ION TRAP MASS SPECTROMETRY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PATHOGENESIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; RAT; TIME OF FLIGHT MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ACYLCARNITINE; ALLIUM MACROSTEMON; DEPRESSION; LIPIDOMICS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY;

ALLIUM; ANIMALS; ANTIDEPRESSIVE AGENTS; CARNITINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DISEASE MODELS, ANIMAL; LIPIDS; MALE; MASS SPECTROMETRY; MEDICINE, CHINESE TRADITIONAL; METABOLOME; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, WISTAR;

EID: 84888256463     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.10.045     Document Type: Article

References (40)

1. Richards D. Prevalence and clinical course of depression: a review. Clin. Psychol. Rev. 2011, 31:1117-1125.
2. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder. JAMA 2003, 289:3095-3105.
3. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?. World Psychiatry 2010, 9:155-161.
4. Gartlehner G., Hansen R.A., Reichenpfader U., Kaminski A., Kien C., Strobelberger M., Van Noord M., Thieda P., Thaler K., Gaynes B. Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report 2011, Oregon Health & Science University, Portland.
5. Cascade E., Kalali A.H., Kennedy S.H. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009, 6:16-18.
6. Akhondzadeh S., Tahmacebi-Pour N., Noorbala A.-A., Amini H., Fallah-Pour H., Jamshidi A.-H., Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother. Res. 2005, 19:148-151.
7. Darbinyan V., Aslanyan G., Amroyan E., Gabrielyan E., Malmström C., Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord. J. Psychiatry 2007, 61:343-348.
8. Su Z.H., Li S.Q., Zou G.A., Yu C.Y., Sun Y.G., Zhang H.W., Gu Y., Zou Z.M. Urinary metabonomics study of anti-depressive effect of Chaihu-Shu-Gan-San on an experimental model of depression induced by chronic variable stress in rats. J. Pharm. Biomed. Anal. 2011, 55:533-539.
9. Zhou Y., Lu L., Li Z., Gao X., Tian J., Zhang L., Wu B., Qin X. Antidepressant-like effects of the fractions of Xiaoyaosan on rat model of chronic unpredictable mild stress. J. Ethnopharmacol. 2011, 137:236-244.
10. Lee S., Kim D.H., Lee C.H., Jung J.W., Seo Y.T., Jang Y.P., Ryu J.H. Antidepressant-like activity of the aqueous extract of Allium macrostemon in mice. J. Ethnopharmacol. 2010, 131:386-395.
11. Vinayavekhin N., Homan E.A., Saghatelian A. Exploring disease through metabolomics. ACS Chem. Biol. 2010, 5:91-103.
12. Han X., Yang K., Gross R.W. Multi-dimensional mass spectrometry-based shotgun lipidomics and novel strategies for lipidomic analyses. Mass Spectrom. Rev. 2012, 31:134-178.
13. Oresic M., Tang J., Seppanen-Laakso T., Mattila I., Saarni S.E., Saarni S.I., Lonnqvist J., Sysi-Aho M., Hyotylainen T., Perala J., Suvisaari J. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011, 3:19.
14. Martinac M., Karlovic D., Vrkic N., Marcinko D., Bazina N., Babic D. Serum lipids in a depressive disorder with regard to depression type. Biochem. Med. (Zagreb) 2007, 17:94-101.
15. Assies J., Pouwer F., Lok A., Mocking R.J.T., Bockting C.L.H., Visser I., Abeling N.G.G.M., Duran M., Schene A.H. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS One 2010, 5:e10635.
16. Lee L.H.W., Shui G.H., Farooqui A.A., Wenk M.R., Tan C.H., Ong W.Y. Lipidomic analyses of the mouse brain after antidepressant treatment: evidence for endogenous release of long-chain fatty acids?. Int. J. Neuropsychopharmacol. 2009, 12:953-964.
17. Khalid A., Lal N., Trivedi J.K., Dalal P.K., Asthana O.P., Srivastava J.S., Akhtar A. Serum lipids: new biological markers in depression?. Indian J. Psychiatry 1998, 40:217-223.
18. Hu C.X., van Dommelen J., van der Heijden R., Spijksma G., Reijmers T.H., Wang M., Slee E., Lu X., Xu G.W., van der Greef J., Hankemeier T. RPLC-Ion-Trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. J. Proteome Res. 2008, 7:4982-4991.
19. Yamada T., Uchikata T., Sakamoto S., Yokoi Y., Fukusaki E., Bamba T. Development of a lipid profiling system using reverse-phase liquid chromatography coupled to high-resolution mass spectrometry with rapid polarity switching and an automated lipid identification software. J. Chromatogr. A 2013, 1292:211-218.
20. Zhang F.X., Jia Z.H., Gao P., Kong H.W., Li X., Lu X., Wu Y.L., Xu G.W. Metabonomics study of urine and plasma in depression and excess fatigue rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Mol. Biosyst. 2010, 6:852-861.
21. Pettegrew J.W., Levine J., McClure R.J. Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry 2000, 5:616-632.
22. Fingerhut R., Ensenauer R., Rochinger W., Arnecke R., Olgemoller B., Roscher A.A. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency. Anal. Chem. 2009, 81:3571-3575.
23. Zuniga A., Li L. Ultra-high performance liquid chromatography tandem mass spectrometry for comprehensive analysis of urinary acylcarnitines. Anal. Chim. Acta 2011, 689:77-84.
24. Ishihara Y., Iijima H., Yagi Y., Hoshi H., Matsunaga K. Inhibition of decrease in natural killer cell activity in repeatedly restraint-stressed mice by a biological response modifier derived from cultured mycelia of the basidiomycete Tricholoma matsutake. Neuroimmunomodulation 2004, 11:41-48.
25. Pham K., Nacher J., Hof P.R., McEwen B.S. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur. J. Neurosci. 2003, 17:879-886.
26. Li W., Li Q.-J., An S.-C. Preventive effect of estrogen on depression-like behavior induced by chronic restraint stress. Neurosci. Bull. 2010, 26:140-146.
27. Gika H.G., Theodoridis G.A., Wingate J.E., Wilson I.D. Within-day reproducibility of an HPLC-MS-Based method for metabonomic analysis: application to human urine. J. Proteome Res. 2007, 6:3291-3303.
28. Zelena E., Dunn W.B., Broadhurst D., Francis-McIntyre S., Carroll K.M., Begley P., O'Hagan S., Knowles J.D., Halsall A., Wilson I.D., Kell D.B., Consortium H. Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal. Chem. 2009, 81:1357-1364.
29. Hu C., Hoene M., Zhao X., Haring H.U., Schleicher E., Lehmann R., Han X., Xu G., Weigert C. Lipidomics analysis reveals efficient storage of hepatic triacylglycerides enriched in unsaturated fatty acids after one bout of exercise in mice. PLoS One 2010, 5:e13318.
30. Chen S., Hoene M., Li J., Li Y., Zhao X., Häring H.-U., Schleicher E.D., Weigert C., Xu G., Lehmann R. Simultaneous extraction of metabolome and lipidome with methyl tert-butyl ether from a single small tissue sample for ultra-high performance liquid chromatography/mass spectrometry. J. Chromatogr. A 2013, 1298:9-16.
31. E lipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res. 2010, 9:2377-2389.
32. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Nat. Acad. Sci. U.S.A. 1988, 85:2805-2809.
33. Kume N., Cybulsky M.I., Gimbrone M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 1992, 90:1138-1144.
34. Kume N., Gimbrone M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 1994, 93:907-911.
35. Huang Y.H., Schafer-Elinder L., Wu R., Claesson H.E., Frostegard J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin. Exp. Immunol. 1999, 116:326-331.
36. Huang F., Subbaiah P.V., Holian O., Zhang J.H., Johnson A., Gertzberg N., Lum H. Lysophosphatidylcholine increases endothelial permeability: role of PKC alpha and RhoA cross talk. Am. J. Physiol.-Lung C. 2005, 289:L176-L185.
37. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
38. Houten S., Wanders R. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J. Inherit. Metab. Dis. 2010, 33:469-477.
39. Adams S.H., Hoppel C.L., Lok K.H., Zhao L., Wong S.W., Minkler P.E., Hwang D.H., Newman J.W., Garvey W.T. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J. Nutr. 2009, 139:1073-1081.
40. Camacho T.C., Roberts R.E., Lazarus N.B., Kaplan G.A., Cohen R.D. Physical activity and depression evidence from the Alameda county study. Am. J. Epidemiol. 1991, 134:220-231.